Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00103428
What this trial is testing

Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Cell Genesys 69
Testing effectiveness (Phase 2)Study completedNCT02507570
What this trial is testing

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

Who this might be right for
Prostate Carcinoma Metastatic to the Bone
Carolina Research Professionals, LLC 40
Large-scale testing (Phase 3)Study completedNCT00002723
What this trial is testing

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 390
Very early researchStudy completedNCT01050842
What this trial is testing

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate CancerAdenocarcinoma of the ProstateHormone-resistant Prostate Cancer+1 more
Mayo Clinic 18
Testing effectiveness (Phase 2)Study completedNCT01260688
What this trial is testing

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Who this might be right for
Hormone Refractory Prostate CancerRecurrent Prostate Cancer
National Cancer Institute (NCI) 22
Not applicableUnknownNCT00133900
What this trial is testing

Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy

Who this might be right for
Hormone Refractory Prostate CancerProstate Cancer
Immunicon 276
Testing effectiveness (Phase 2)Study completedNCT00005028
What this trial is testing

Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
University of Maryland, Baltimore 46
Large-scale testing (Phase 3)Study completedNCT00003232
What this trial is testing

Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer

Who this might be right for
PainProstate CancerQuality of Life
NCIC Clinical Trials Group 227
Testing effectiveness (Phase 2)Ended earlyNCT00582582
What this trial is testing

Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
University of Wisconsin, Madison 70
Testing effectiveness (Phase 2)Study completedNCT00427999
What this trial is testing

Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 67
Post-approval studies (Phase 4)Study completedNCT00280098
What this trial is testing

Docetaxel in the Treatment of Hormone Refractory Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Sanofi 30
Testing effectiveness (Phase 2)Ended earlyNCT00918385
What this trial is testing

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Duke University 57
Testing effectiveness (Phase 2)Study completedNCT00111618
What this trial is testing

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Antisoma Research 70
Testing effectiveness (Phase 2)Study completedNCT02182063
What this trial is testing

A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Boehringer Ingelheim 81
Testing effectiveness (Phase 2)Study completedNCT00642018
What this trial is testing

An Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Eli Lilly and Company 154
Large-scale testing (Phase 3)Study completedNCT00950911
What this trial is testing

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Who this might be right for
Bone Metastases in Men With Hormone-Refractory Prostate CancerBone Metastases in Subjects With Advanced Breast CancerBone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Amgen 35
Early research (Phase 1)Study completedNCT00002721
What this trial is testing

Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
University of New Mexico 18
Testing effectiveness (Phase 2)Study completedNCT00003626
What this trial is testing

Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy

Who this might be right for
Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Testing effectiveness (Phase 2)Study completedNCT00757692
What this trial is testing

Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.

Who this might be right for
Prostate Cancer
British Columbia Cancer Agency 74
Testing effectiveness (Phase 2)Study completedNCT00058084
What this trial is testing

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
National Cancer Institute (NCI) 80
Next Page